CAPR Evp, General Counsel Karen Krasney Sells 500 Shares

Karen Krasney, Executive Vice President and General Counsel at Capricor Therapeutics, Inc. (NasdaqGS:CAPR), sold 500 shares of the company on June 22, 2026. This transaction was not part of a pre-planned trading program, and the shares were sold at an undisclosed price. Shares of Capricor traded near $29.60 on Thursday.

Insider Buying and Selling at Capricor Therapeutics, Inc.

In addition to Karen Krasney's sale, there were other insider transactions at Capricor Therapeutics. On June 24, 2026, Chief Financial Officer Anthony Bergmann both bought and sold 400 shares at different prices, including a purchase at $3.18 per share and a sale at $30.00 per share. Krasney also bought 400 shares at $3.18 and sold another 400 shares at $30.00 on the same day.

Other Institutional Activity in Capricor Therapeutics

Several institutional investors have adjusted their stakes in Capricor Therapeutics. Suvretta Capital Management, LLC significantly increased its holdings by adding 2,032,990 shares, bringing its total to 3,818,600 shares worth approximately $116.1 million. BlackRock, Inc. also boosted its position by 570,837 shares, now holding 3,421,815 shares valued at around $104 million. Tang Capital Management LLC doubled its stake, adding 1,699,900 shares, resulting in a total of 3,399,900 shares worth about $103.4 million. State Street Corp increased its shares by 1,352,380, now holding 2,181,901 shares with a value of approximately $66.3 million. Vanguard Capital Management LLC opened a new position with 2,027,732 shares, valued at roughly $61.6 million.

Capricor Therapeutics, Inc. Stock Up 225.7%

Capricor Therapeutics, Inc. (NasdaqGS:CAPR) has a market cap of approximately $1.70 billion. The stock's forward P/E ratio is not meaningful as the company is not currently profitable. It has a beta of 0.368, suggesting lower volatility compared to the market. The 52-week range for the stock is between $4.30 and $40.37. Capricor's 50-day moving average is $30.58, while the 200-day moving average stands at $21.38. The company maintains a strong liquidity position with a current ratio of 8.42 and a quick ratio of 8.28, though it has a debt-to-equity ratio of 5.31.

Analysts Set New Price Targets

Analysts continue to show optimism for Capricor Therapeutics. On March 13, 2026, B. Riley Securities maintained its buy rating with a $63 price target. Piper Sandler reiterated its buy rating with a $58 target on the same date. HC Wainwright & Co. also reiterated a buy rating with a $60 target on March 10, 2026. Overall, the consensus among analysts is a strong buy, with a mean price target of $54.11 based on nine analyst opinions.

About Capricor Therapeutics

Capricor Therapeutics, Inc. is a biotechnology company focused on developing innovative cell and exosome-based treatments for diseases with unmet medical needs, such as Duchenne muscular dystrophy (DMD). Based in San Diego, California, the company is led by CEO Dr. Linda Marbán. Capricor's lead candidate, Deramiocel, is in phase 3 clinical trials for DMD. The company is also working on an exosome-based vaccine for SARS-CoV-2, among other projects.

Bottom Line

Karen Krasney's recent sale of Capricor shares is part of a series of insider transactions at the company. Investors should note that these moves are reported after the fact and do not necessarily indicate future stock performance. With strong institutional support and positive analyst ratings, Capricor remains a stock to watch in the biotechnology sector.